RNS Number: 9939N Kromek Group PLC 23 June 2025

23 June 2025

Kromek Group plc ("Kromek" or the "Group")

Capital Markets Day Presentation

Kromek (AIM: KMK),a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, is pleased to announce that a recording of the presentation delivered at its capital markets day held on 18 June 2025 is available on the Group's website at: https://www.kromek.com/cmd-25/.

The recording is also available on the Investor Meet Company platform where the Group will be hosting an online Q&A session for retail investors at 5.00pm on Wednesday 25 June 2025. Investors can sign up to Investor Meet Company for free and register to attend the Kromek Q&A session via:

https://www.investormeetcompany.com/kromek-group-plc/register-investor.

Kromek Group plc

Arnab Basu, CEO Claire Burgess. CFO +44 (0)1740 626 060

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance

+44 (0)20 7220 0500

Tim Redfern - ECM Michael Johnson - Sales

Gracechurch Group (Financial PR)

Harry Chathli/Claire Norbury/Henry Gamble

+44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact msc.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END